TMC207: The first compound of a new class of potent anti-tuberculosis drugs

Future Microbiology

Volumn 5, Issue 6, 2010, Pages 849-858

  Matteelli, Alberto ^a   Carvalho, Anna C C ^a   Dooley, Kelly E ^b   Kritski, Afranio ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Diarylquinolines; R207910; TMC207; Tuberculosis

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; ANTIRETROVIRUS AGENT; ETHAMBUTOL; ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BACTERICIDAL ACTIVITY; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG CONTROL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EYE DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MORNING DOSAGE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIPLE DRUG DOSE; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SPUTUM CULTURE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; ATP SYNTHETASE COMPLEXES; BACTERIAL PROTEINS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; TREATMENT OUTCOME; TUBERCULOSIS;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 77953242571     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.50     Document Type: Review

References (45)

1. WHO: Global tuberculosis control: surveillance, planning, financing. WHO report 2009. WHO/HTM/TB/2009.411. WHO, Geneva, Switzerland (2009).
2. WHO: An expanded DOTS framework for effective tuberculosis control. WHO/CDS/ STB/2001.16. WHO, Geneva, Switzerland (2001).
3. Raviglione MC, Uplekar M: WHO's new Stop TB strategy. Lancet 367, 952-955 (2006).
4. Sharma SK, Liu JJ: Progress of DOTS in global tuberculosis control. Lancet 367, 950-952 (2006).
5. WHO: Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol. Rec. 81, 430-432 (2006).
6. Leading Edge: The tuberculosis X factor. Lancet Infect. Dis. 6, 679 (2006).
7. Dye C, Espinal MA: Will tuberculosis become resistant to all antibiotics? Proc. R. Soc. 268, 45-52 (2001).
8. Dye C, Williams BG: Criteria for the control of drug-resistant tuberculosis. Proc. Natl Acad. Sci. USA 97, 8180-8185 (2000).
9. Basu S, Andrews JR, Poolman EM et al.: Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 370, 1500-1507 (2007).
10. Matteelli A, Migliori GB, Cirillo D, Centis R, Girardi E, Raviglione R: Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev. Anti Infect. Ther. 5, 857-871 (2007).
11. Spigelman MK: New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196, S28-S34 (2007).
12. Ballel L, Field RA, Duncan K, Young RJ: New small-molecule synthetic antimycobacterials. Antimicrob. Agents Chemother. 49, 2153-2163 (2005).
13. Janin Yl: Antituberculosis drugs: ten years of research. Bioorg. Med. Chem. 15, 2479-2513 (2007).
14. van Daele I, van Calenbergh S: Patent developments in antimycobacterial small-molecule. Expert Opin. Ther. Patents 15, 131-140 (2005).
15. Barry CE: Unorthodox approach to the development of a new antituberculosis therapy. N. Engl. J. Med. 360, 2466-2467 (2009).
16. Andries K, Verhasselt P, Guillemont J et al.: A diaryquinoline drug active on ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227 (2005).
17. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V: Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother. 50, 3543-3547 (2006).
18. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N: Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am. J. Respir. Crit. Care Med. 180, 553-557 (2009).
19. Diacon AH, Pym AP, Grobush M et al.: The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360, 2397-2405 (2009).
20. Lounis N, Guillemont J, Veziris N, Koul A, Jarlier V, Andries K: R207910 (TMC207): a new antibiotic for the treatment of tuberculosis. Med. Mal. Infect. DOI: 10.1016/j.medmal.2009.09.007 (2009) (Epub ahead of print).
21. Gaurrand S, Desjardins S, Meyer C et al.: Conformational analysis of R207910, a new candidate for the treatment of tuberculosis, by a combined NMR and molecular modelling approach. Chem. Biol. Drug Design 68, 77-84 (2006).
22. Petit S, Coquerel G, Meyer C, Guillemont J: Absolute configuration and structural features of R2071910, a novel anti-tuberculosis agent. J. Mol. Struct. 837, 252-256 (2007).
23. Koul A, Dendouga N, Vergauwen K et al.: Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3, 323-324 (2007).
24. Petrella S, Cambau E, Chauffour A, Andries K, Jarlier V, Sougakoff W: Genetic basis for natural and acquired resistance of the diaryquinoline R207910 in mycobacteria. Antimicrob. Agents Chemother. 50, 2853-2856 (2006).
25. Huitric E, Verhasselt P, Andries K, Hoffner SE: In vitro antimycobacterial spectrum of a diarylquinoline ATP-synthase inhibitor. Antimicrob. Agents Chemother. 51, 4202-4204 (2007).
26. Shi L, Sohaskey CD, Kana BD et al.: Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and in vitro conditions affecting aerobic respiration. Proc. Natl Acad. Sci. USA 102, 15629-15634 (2005).
27. Rao SP, Alonso S, Rand L, Dick T, Pethe K: The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 105, 11945-11950 (2008).
28. Koul A, Vranckx L, Dendouga N et al.: Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283, 25273-25280 (2008).
29. Louis N, Gevers T, Van den Berg J, Vranchkx L, Andreis K: ATP synthase inhibition of Mycobacterium avium is not bactericidal. Antimicrob. Agents Chemother. 53, 4927-4929 (2009).
30. Rustomjee R, Diacon AH, Allen J et al.: Early bactericidal activity and pharmacokinetics of the dairylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52, 2831-2835 (2008).
31. van Heeswijk R, Lachaert R, Leopold L, DeBeule K, McNeeley D: The effect of CYP3A4 inhibition on the clinical pharmacokinetics of TMC207. Presented at: the 38th Union World Conference on Lung Health. Cape Town, South Africa, 8-12 November 2007 (Poster PS-71358-71311).
32. Lenaerts AJ, Hoff D, Aly S et al.: Location of persisting mycobacteria in guinea pig model of tuberculosis revealed by R207910. Antimicrob. Agents Chemother. 51, 3338-3345 (2007).
33. Ibrahim M, Andries K, Lounis N et al.: Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob. Agents Chemother. 51, 1011-1015 (2007).
34. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z: Mode of action of pyrazinamide: dysruption of Mycobacterium tuberculosis membrane transport and energetics by pirazinoic acid. J. Antimicrob. Chemother. 52, 790-795 (2003).
35. Veziris N, Ibrahim M, Lounis N et al.: A once weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 179, 75-79 (2009).
36. Lounis N, Gevers T, Van den Berg J, Andries K: Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob. Agents Chemother. 52, 3568-3572 (2008).
37. Nuermberger EL, Yoshimatsu T, Tyagi S et al.: Moxifloxacine-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170, 1131-1134 (2004).
38. Nuermberger E: Once weekly treatment of tuberculosis with the diarylquinoline R207910. Am. J. Respir. Crit. Care Med. 179, 2-3 (2009).
39. Gelber R, Andries K, Paredes RM, Andaya CE, Burgos J: The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently. Antimicrob. Agents Chemother. 53, 3989-3991 (2009).
40. Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W: Randomised trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med. 4, e292 (2007).
41. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ et al.: Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother. 53, 1290-1292 (2009).
42. Sacks LV, Behrman LE: Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective. Tuberculosis 88(Suppl. 1), S93-S100 (2008).
43. Benator D, Bhattacharya M, Bozeman L et al.: Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360, 528-534 (2002).
44. Vernon A, Burman W, Benator D, Khan A, Bozeman L: Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 353, 1843-1847 (1999).
45. Weiner M, Burman W, Vernon A et al.: Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am. J. Respir. Crit. Care Med. 167, 1341-1347 (2003).